
TY  - JOUR
TI  - EACS 2019 – Abstract Book
JO  - HIV Medicine
JA  - HIV Med
VL  - 20
IS  - S9
SN  - 1464-2662
UR  - https://doi.org/10.1111/hiv.12814
DO  - doi:10.1111/hiv.12814
SP  - 3
EP  - 316
PY  - 2019
ER  - 

TY  - JOUR
TI  - Abstracts accepted for publication only
JO  - Clinical Microbiology and Infection
VL  - 15
IS  - s4
SN  - 1198-743X
UR  - https://doi.org/10.1111/j.1469-0691.2009.02859.x
DO  - doi:10.1111/j.1469-0691.2009.02859.x
SP  - S613
EP  - S678
PY  - 2009
ER  - 

TY  - JOUR
TI  - Abstract Journal Colorectal Surgery
JO  - ANZ Journal of Surgery
JA  - ANZ Journal of Surgery
VL  - 89
IS  - S1
SN  - 1445-1433
UR  - https://doi.org/10.1111/ans.15184
DO  - doi:10.1111/ans.15184
SP  - 23
EP  - 45
PY  - 2019
ER  - 

TY  - JOUR
TI  - 2012 ASPHO Abstracts
JO  - Pediatric Blood & Cancer
JA  - Pediatr. Blood Cancer
VL  - 58
IS  - 7
SN  - 1545-5009
UR  - https://doi.org/10.1002/pbc.24133
DO  - doi:10.1002/pbc.24133
SP  - 1014
EP  - 1097
PY  - 2012
ER  - 

TY  - JOUR
AU  - Gumbs, AA
TI  - The Endocrine and Pancreatic Unit at the University of Verona, Italy
JO  - HPB
VL  - 4
IS  - 4
SN  - 1365-182X
UR  - https://doi.org/10.1080/13651820260503828
DO  - doi:10.1080/13651820260503828
SP  - 171
EP  - 173
PY  - 2002
ER  - 

TY  - JOUR
TI  - Abstracts cont.
JO  - Clinical Microbiology and Infection
VL  - 11
IS  - s2
SN  - 1198-743X
UR  - https://doi.org/10.1111/j.1469-0691.2005.01135.x
DO  - doi:10.1111/j.1469-0691.2005.01135.x
SP  - 648
EP  - 744
PY  - 2005
ER  - 

TY  - JOUR
TI  - DrugScan Series
JO  - Journal of Pharmacy Practice and Research
JA  - Journal of Pharmacy Practice and Research
VL  - 37
IS  - 2
SN  - 1445-937X
UR  - https://doi.org/10.1002/j.2055-2335.2007.tb00046.x
DO  - doi:10.1002/j.2055-2335.2007.tb00046.x
SP  - 157
EP  - 165
PY  - 2007
AB  - DrugScan is a review of the international literature on therapeutics. Leading pharmacy practitioners scan the literature and present information on major clinical trials, important pharmacoepidemiology studies, and pharmacoeconomic research in a succinct format. Interested readers are encouraged to consult the original publications in greater detail.
ER  - 

TY  - JOUR
TI  - 2018 ACCP Global Conference on Clinical Pharmacy: October 20–23, 2018
JO  - JACCP:  JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY
JA  - J Am Coll Clin Pharm
VL  - 1
IS  - 2
UR  - https://doi.org/10.1002/jac5.1059
DO  - doi:10.1002/jac5.1059
SP  - 122
EP  - 353
PY  - 2018
ER  - 

C7  - pp. 417-425
TI  - Index
SN  - 9783527319350
UR  - https://doi.org/10.1002/9783527626151.index
DO  - doi:10.1002/9783527626151.index
SP  - 417-425
PY  - 2018
ER  - 

TY  - JOUR
AU  - Manzanares, William
AU  - Langlois, Pascal L.
AU  - Heyland, Daren K.
TI  - Pharmaconutrition With Selenium in Critically Ill Patients
JO  - Nutrition in Clinical Practice
JA  - Nutrition in Clinical Practice
VL  - 30
IS  - 1
SN  - 9783527319350
UR  - https://doi.org/10.1177/0884533614561794
DO  - doi:10.1177/0884533614561794
SP  - 34
EP  - 43
KW  - critical care
KW  - critical illness
KW  - sepsis
KW  - systemic inflammatory response syndrome
KW  - selenium
KW  - antioxidants
KW  - nutritional support
PY  - 2015
AB  - Selenium is a component of selenoproteins with antioxidant, anti-inflammatory, and immunomodulatory properties. Systemic inflammatory response syndrome (SIRS), multiorgan dysfunction (MOD), and multiorgan failure (MOF) are associated with an early reduction in plasma selenium and glutathione peroxidase activity (GPx), and both parameters correlate inversely with the severity of illness and outcomes. Several randomized clinical trials (RCTs) evaluated selenium therapy as monotherapy or in antioxidant cocktails in intensive care unit (ICU) patient populations, and more recently several meta-analyses suggested benefits with selenium therapy in the most seriously ill patients. However, the largest RCT on pharmaconutrition with glutamine and antioxidants, the REducing Deaths due to Oxidative Stress (REDOXS) Study, was unable to find any improvement in clinical outcomes with antioxidants provided by the enteral and parenteral route and suggested harm in patients with renal dysfunction. Subsequently, the MetaPlus study demonstrated increased mortality in medical patients when provided extra glutamine and selenium enterally. The treatment effect of selenium may be dependent on the dose, the route of administration, and whether administered with other nutrients and the patient population studied. Currently, there are few small studies evaluating the pharmacokinetic profile of intravenous (IV) selenium in SIRS, and therefore more data are necessary, particularly in patients with MOD, including those with renal dysfunction. According to current knowledge, high-dose pentahydrate sodium selenite could be given as an IV bolus injection (1000?2000 µg), which causes transient pro-oxidant, cytotoxic, and anti-inflammatory effects, and then followed by a continuous infusion of 1000?1600 µg/d for up to 10?14 days. Nonetheless, the optimum dose and efficacy still remain controversial and need to be definitively established.
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - International Journal of Rheumatic Diseases
JA  - Int J Rheum Dis
VL  - 16
IS  - s1
SN  - 9783527319350
UR  - https://doi.org/10.1111/1756-185X.12173
DO  - doi:10.1111/1756-185X.12173
SP  - 1
EP  - 122
PY  - 2013
ER  - 

TY  - JOUR
TI  - Posters
JO  - Clinical Microbiology and Infection
VL  - 13
IS  - s1
SN  - 9783527319350
UR  - https://doi.org/10.1111/j.1469-0691.2007.01733.x
DO  - doi:10.1111/j.1469-0691.2007.01733.x
SP  - S109
EP  - S608
PY  - 2007
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Respirology
VL  - 16
IS  - s2
SN  - 9783527319350
UR  - https://doi.org/10.1111/j.1440-1843.2011.02071.x
DO  - doi:10.1111/j.1440-1843.2011.02071.x
SP  - 1
EP  - 326
PY  - 2011
ER  - 

TY  - JOUR
TI  - R1885 - R2270
JO  - Clinical Microbiology and Infection
VL  - 12
IS  - s4
SN  - 9783527319350
UR  - https://doi.org/10.1111/j.1470-9465.2006.12_4_1432.x
DO  - doi:10.1111/j.1470-9465.2006.12_4_1432.x
PY  - 2006
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - British Journal of Haematology
JA  - Br J Haematol
VL  - 181
IS  - S1
SN  - 9783527319350
UR  - https://doi.org/10.1111/bjh.15226
DO  - doi:10.1111/bjh.15226
SP  - 5
EP  - 211
PY  - 2018
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - Acta Paediatrica
VL  - 98
IS  - s460
SN  - 9783527319350
UR  - https://doi.org/10.1111/j.1651-2227.2009.01482_2.x
DO  - doi:10.1111/j.1651-2227.2009.01482_2.x
SP  - 69
EP  - 278
PY  - 2009
ER  - 

TY  - JOUR
TI  - Colorectal Surgery Program Abstracts
JO  - ANZ Journal of Surgery
JA  - ANZ J Surg
VL  - 84
IS  - S1
SN  - 9783527319350
UR  - https://doi.org/10.1111/ans.12609
DO  - doi:10.1111/ans.12609
SP  - 30
EP  - 52
PY  - 2014
ER  - 

TY  - JOUR
TI  - Obstetric/Paediatric Anasthesia
JO  - Acta Anaesthesiologica Scandinavica
VL  - 40
IS  - s109
SN  - 9783527319350
UR  - https://doi.org/10.1111/j.1399-6576.1996.tb04601.x
DO  - doi:10.1111/j.1399-6576.1996.tb04601.x
SP  - 245
EP  - 253
PY  - 1996
ER  - 

AU  - Philippart, François
AU  - Cavaillon, Jean-Marc
AU  - Dinarello, Charles
C7  - pp. 175-204
TI  - Inflammatory Mediators
SN  - 9783527319350
UR  - https://doi.org/10.1002/9783527626151.ch8
DO  - doi:10.1002/9783527626151.ch8
SP  - 175-204
KW  - inflammatory mediators
KW  - cytokines
KW  - growth factor
KW  - complement system
KW  - lipid mediators
KW  - nitric oxide (NO)
KW  - cellular markers
PY  - 1996
AB  - Summary This chapter contains sections titled: Inflammatory Mediators in Sepsis Inflammatory Mediators in Non-infectious SIRS Conclusion References
ER  - 

TY  - JOUR
TI  - Abstracts cont.
JO  - Clinical Microbiology and Infection
VL  - 11
IS  - s2
SN  - 9783527319350
UR  - https://doi.org/10.1111/j.1469-0691.2005.clm_1134_04.x
DO  - doi:10.1111/j.1469-0691.2005.clm_1134_04.x
SP  - 546
EP  - 646
PY  - 2005
ER  - 
